Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF) — PREFER-HF  

Heart Failure With Normal Ejection Fraction Clinical Trial

Official title: Effects of Intravenous Iron Therapy With Ferric Carboxymaltose Compared With Oral Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

Status Recruiting

Clinical Trial Summary

The purpose of the study is to evaluate whether the administration of iron to patients with heart failure and preserved ejection fraction results in an improvement of symptoms and functional class, in addition to evaluating whether oral iron is equivalent to intravenous iron to achieve this improvement.

Clinical Trial Description

Iron deficiency is one of the most prevalent co-morbid conditions in chronic heart failure. In the absence of any iron treatment, it is estimated that up to 50% of patients with heart failure have low levels of available iron. Treatment with intravenous iron improves exercise tolerance , quality of life , and reduces hospitalization in patients with chronic heart failure and reduced ejection fraction. However data on the effect of iron therapy in patients with heart failure with preserved ejection fraction are still lacking. The evidence related to oral iron therapy in HF is limited and no randomized trials compared oral iron vs no iron therapy in the absence of erythropoiesis-stimulating agents. ;

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Ferropenic Anemia
• Heart Failure
• Heart Failure With Normal Ejection Fraction

• NCT number: NCT03833336
• Study type: Interventional
• Source: Institut de Recerca Biomèdica de Lleida
• Contact: Jose Luis Morales-Rull, MD,PhD
• Phone: 0034+616424858
• Email: jl.moralesrull@gmail.com
• Status: Recruiting
• Phase: Phase 3
• Start date: August 23, 2017
• Completion date: June 2020